Covid has created many challenges globally for every type of company… MedolifeRx included .. however, while covid has impeded some of the roll out events for new products (like large group gatherings etc) … covid may very well be the catalyst that helps escozine get through the fda quicker (as opposed to first being put forth as a cancer drug… once covid therapeutic gets fda approval then they’ll subsequently be putting escozine forth in the cancer realm and should be a lot quicker then as escozine as an ingredient will already have had garnered approval) The Dominican Republic has agreed to use escozine as part of its nations covid protocol which will in turn be the opening for other Latin American countries to be introduced to escozine as a covid therapeutic. It’s clear covid isn’t going anywhere - sadly, it’s only just evolving… thus far it’s my understanding that it’s been reported that escozine has proven as an effective therapeutic against all the variants thus far…. The Nagoya protocol is not only a good thing for the country/ citizens / ecology of the country in which a biological is sourced … but also, the fact MedolifeRx has this relationship established with the Dominican Republic bodes well for us as investors - ie the Nagoya protocol with the DR and MedolifeRx / Dr Mikaelian is a good thing … the $cience I invested in is the reason I’m still holding … GLTA escozine MedolifeRx Imunapen QNTA
I’m still using the imunapen daily - so far seems to be doing a great job in assisting my immune system :)
News 
Market Data 
Discover 
